Back
Monday, 15 Mar, 2021
Arcturus to test single-dose vaccine in large phase 3 trials (Straits Times)
US-based Arcturus Therapeutics, which is jointly developing a COVID-19 vaccine with Duke-NUS, is preparing to test a single low-dose shot of its messenger RNA vaccine in large trials that will start in the second quarter of the year. The 5 microgram single-dose regimen will also be a lyophilised, or freeze-dried, version that will be easier and less costly to distribute and store, not requiring the cold chain storage and transport that mRNA vaccines in frozen liquid form need.
Original article: Arcturus to test single-dose vaccine in large phase 3 trials (Straits Times)